FindTrial
Sign In

Insulin Lispro mixtures (mid mixture and low mixture) administered three times daily compared with human insulin 30/70 administered twice daily in insulin-requiring patients with type 2 diabetes

Insulin Lispro mixtures (mid mixture and low mixture) administered three times daily compared with human insulin 30/70 administered twice daily in insulin-requiring patients with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN77659599
Enrollment
Unknown
Registered
2003-09-12
Start date
2000-05-11
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Type 2 Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

4 Weeks on 30/70 insulin bd then randomised to continue with 30/70 or start lispro mixes for 16 weeks. After 16 weeks crossover to comparator treatment.

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 35 years and over with type 2 diabetes and using insulin.

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

MeasureTime frame
1. Improvement in HbA1c levels 2. Improvement in home blood glucose measurements 3. Comparison of fructosamine 4. Comparison of doses 5. Comparison of hypoglycaemic episodes—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026